- Mid-year economic review set to make a comeback, maybe out in December
- Can India drive Apple towards world's 1st trillion dollar company?
- Lok Sabha passes fugitive economic offenders bill as Oppn attacks govt
- Check fake news or face legal action, Govt warns WhatsApp in second notice
- Rupee slips 43 paise against dollar; ends at a lifetime low of 69.05
- Karnataka SSLC supplementary result 2018 out; check at kseeb.kar.nic.in
- NCLT approves J K Papers' resolution plan for revival of Sirpur Paper Mills
- Kotak Mahindra Bank consolidated Q1 net up 17% to Rs 15.74 bn
Aurobindo Pharma Ltd.
|BSE: 524804||Sector: Health care|
|NSE: AUROPHARMA||ISIN Code: INE406A01037|
|BSE 00:00 | 19 Jul||569.05||
|NSE 00:00 | 19 Jul||567.85||
|Mkt Cap.(Rs cr)||33,341|
|Mkt Cap.(Rs cr)||33340.64|
Aurobindo Pharma Ltd. (AUROPHARMA) - Latest News & Headlines
6.48 am | 17 Jul 2018 | Business Standard
Unlikely to add to profits in first 2 years; working capital may rise
11.08 am | 15 Jul 2018 | Business Standard
BS ReporterHyderabad, 14 July: Aurobindo Pharma Limited announced today that its step-down subsidiary Agile Pharma B V(Netherlands ) signed a definiti...
11.49 pm | 11 Jul 2018 | Business Standard
Street cautious as Mallinckrodt biz is declining amid enhanced scrutiny on opioid drugs
3.25 pm | 3 Jul 2018 | Business Standard
At 02:43 pm; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.3% as compared to 0.46% rise in the Nifty 50 index.
1.25 am | 29 Jun 2018 | Business Standard
Analysts at Elara Capital say Ertapenem approval gives comfort to Aurobindo's ability to grow its US business in FY19, despite the high base
12.22 pm | 15 Jun 2018 | Business Standard
At 11:23 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week.
3.29 pm | 14 Jun 2018 | Business Standard
At 03:16 pm; the Nifty Pharma index, the sole gainer among sectoral indices, was up 2%, as compared to 0.49% decline in Nifty 50 index.
2.14 pm | 12 Jun 2018 | Business Standard
Marksans Pharma, Alembic Pharma, Caplin Point Lab, Ajanta Pharma, Bliss GVS Pharma, Granules India, Aurobindo Pharma and Wockhardt were up in the rang...
11.25 pm | 29 May 2018 | Business Standard
Large US portfolio, lower price erosion expected to drive earnings
7.01 am | 8 May 2018 | Business Standard
---- Places a non-binding initial bid of $1.6 bn for the US assets ---- Analysts feel Aurobindo's bid is aggressively placed for low margin assets
6.45 am | 4 Apr 2018 | Business Standard
Higher number of approvals from April 2018, repeated regulatory issues and lower profits from niche opportunities are some of the concerns
6.53 pm | 11 Mar 2018 | Press Trust of India
FDA also observed that Aurobindo Pharma employees lack the training required to perform their assigned functions
11.14 pm | 8 Mar 2018 | Business Standard
Analysts said given the strong European prospects and as most concerns relating to unit-IV are priced in, downside was limited for the stock
9.48 pm | 8 Mar 2018 | Business Standard
Europe is the third-largest market for Indian drug makers after the US and Africa
9.45 am | 5 Mar 2018 | Business Standard
The stock dipped 5.4% to Rs 590 on the BSE after the media report suggested that the company received nine observations from the US drug regulator for...
4.42 pm | 4 Mar 2018 | Business Standard
BS ReporterHyderabad, 4 March: The US Food and Drug Administration(USFDA) has issued Form 483 with 9 observations to Aurobindo Pharma Limited's unit 4...
11.24 pm | 19 Feb 2018 | Business Standard
While Lupin recorded a 10.6 per cent decline in its sales for the period, the largest, Sun Pharma, recorded a 17.4 per cent fall
11.53 pm | 9 Feb 2018 | Business Standard
Company has already received highest number of USFDA approvals since April 2017 and aims to launch 75% of these
7.48 pm | 7 Feb 2018 | Business Standard
BS ReporterHyderabad, 7 February: Aurobindo Pharma Limited has reported a 2.8 percent increase in consolidated net profit at Rs 5.95 billion for the q...
8.43 am | 31 Jan 2018 | Business Standard
Nifty outlook and few trading ideas by Vaishali Parekh, Research Analyst - Technical Research at Prabhudas Lilladher